Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy

John Holland, Patrick S. Swift

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

PURPOSE: To evaluate treatment tolerance in patients with and without the human immunodeficiency virus (HIV) who were undergoing treatment of anal cancer. MATERIALS AND METHODS: The authors retrospectively reviewed the medical records of 62 patients with anal cancer who received radiation treatment. Seven patients had HIV, four of whom had acquired immunodeficiency syndrome. Fifty-five patients were HIV negative, including 11 patients identified as being at high risk for HIV infection whose status was unknown. RESULTS: Thirty of the 55 (55%) patients who were HIV negative required treatment breaks of a mean duration of 16.7 days. Four of those 55 (7%) patients required hospitalization. Three of 42 (7%) patients who were HIV negative receiving chemotherapy required chemotherapy dose reduction. All seven patients with HIV required treatment breaks of a mean duration of 21.7 days. Three of the seven (43%) patients required hospitalization. Four of the seven (57%) patients required chemotherapy dose reduction. CONCLUSION: Patients with HIV undergoing treatment of anal cancer have increased toxic reactions to chemoradiation. Treatment must be individually tailored on the basis of extent of disease and degree of compromise of the immune system.

Original languageEnglish (US)
Pages (from-to)251-254
Number of pages4
JournalRadiology
Volume193
Issue number1
StatePublished - Oct 1994
Externally publishedYes

Fingerprint

Radiotherapy
HIV
Carcinoma
Drug Therapy
Anus Neoplasms
Therapeutics
Hospitalization
Poisons
Virus Diseases
Medical Records
Immune System
Acquired Immunodeficiency Syndrome
Radiation

Keywords

  • Acquired immunodeficiency syndrome (AIDS)
  • Anus, neoplasms
  • Chemotherapy
  • Chemotherapy, complications
  • Therapeutic radiology

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. / Holland, John; Swift, Patrick S.

In: Radiology, Vol. 193, No. 1, 10.1994, p. 251-254.

Research output: Contribution to journalArticle

@article{d9b92f7b00a245f9801b7848498b0cb5,
title = "Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy",
abstract = "PURPOSE: To evaluate treatment tolerance in patients with and without the human immunodeficiency virus (HIV) who were undergoing treatment of anal cancer. MATERIALS AND METHODS: The authors retrospectively reviewed the medical records of 62 patients with anal cancer who received radiation treatment. Seven patients had HIV, four of whom had acquired immunodeficiency syndrome. Fifty-five patients were HIV negative, including 11 patients identified as being at high risk for HIV infection whose status was unknown. RESULTS: Thirty of the 55 (55{\%}) patients who were HIV negative required treatment breaks of a mean duration of 16.7 days. Four of those 55 (7{\%}) patients required hospitalization. Three of 42 (7{\%}) patients who were HIV negative receiving chemotherapy required chemotherapy dose reduction. All seven patients with HIV required treatment breaks of a mean duration of 21.7 days. Three of the seven (43{\%}) patients required hospitalization. Four of the seven (57{\%}) patients required chemotherapy dose reduction. CONCLUSION: Patients with HIV undergoing treatment of anal cancer have increased toxic reactions to chemoradiation. Treatment must be individually tailored on the basis of extent of disease and degree of compromise of the immune system.",
keywords = "Acquired immunodeficiency syndrome (AIDS), Anus, neoplasms, Chemotherapy, Chemotherapy, complications, Therapeutic radiology",
author = "John Holland and Swift, {Patrick S.}",
year = "1994",
month = "10",
language = "English (US)",
volume = "193",
pages = "251--254",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy

AU - Holland, John

AU - Swift, Patrick S.

PY - 1994/10

Y1 - 1994/10

N2 - PURPOSE: To evaluate treatment tolerance in patients with and without the human immunodeficiency virus (HIV) who were undergoing treatment of anal cancer. MATERIALS AND METHODS: The authors retrospectively reviewed the medical records of 62 patients with anal cancer who received radiation treatment. Seven patients had HIV, four of whom had acquired immunodeficiency syndrome. Fifty-five patients were HIV negative, including 11 patients identified as being at high risk for HIV infection whose status was unknown. RESULTS: Thirty of the 55 (55%) patients who were HIV negative required treatment breaks of a mean duration of 16.7 days. Four of those 55 (7%) patients required hospitalization. Three of 42 (7%) patients who were HIV negative receiving chemotherapy required chemotherapy dose reduction. All seven patients with HIV required treatment breaks of a mean duration of 21.7 days. Three of the seven (43%) patients required hospitalization. Four of the seven (57%) patients required chemotherapy dose reduction. CONCLUSION: Patients with HIV undergoing treatment of anal cancer have increased toxic reactions to chemoradiation. Treatment must be individually tailored on the basis of extent of disease and degree of compromise of the immune system.

AB - PURPOSE: To evaluate treatment tolerance in patients with and without the human immunodeficiency virus (HIV) who were undergoing treatment of anal cancer. MATERIALS AND METHODS: The authors retrospectively reviewed the medical records of 62 patients with anal cancer who received radiation treatment. Seven patients had HIV, four of whom had acquired immunodeficiency syndrome. Fifty-five patients were HIV negative, including 11 patients identified as being at high risk for HIV infection whose status was unknown. RESULTS: Thirty of the 55 (55%) patients who were HIV negative required treatment breaks of a mean duration of 16.7 days. Four of those 55 (7%) patients required hospitalization. Three of 42 (7%) patients who were HIV negative receiving chemotherapy required chemotherapy dose reduction. All seven patients with HIV required treatment breaks of a mean duration of 21.7 days. Three of the seven (43%) patients required hospitalization. Four of the seven (57%) patients required chemotherapy dose reduction. CONCLUSION: Patients with HIV undergoing treatment of anal cancer have increased toxic reactions to chemoradiation. Treatment must be individually tailored on the basis of extent of disease and degree of compromise of the immune system.

KW - Acquired immunodeficiency syndrome (AIDS)

KW - Anus, neoplasms

KW - Chemotherapy

KW - Chemotherapy, complications

KW - Therapeutic radiology

UR - http://www.scopus.com/inward/record.url?scp=0028146556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028146556&partnerID=8YFLogxK

M3 - Article

VL - 193

SP - 251

EP - 254

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -